Effects of pulmonary artery banding in doxorubicin-induced left ventricular cardiomyopathy

Can Yerebakan, MD, a Johannes Boltze, MD, PhD, b Hatem Elmontaser, MD, c Uygar Yoruker, MD, c Heiner Latus, MD, c Markus Khalil, MD, c Stefan Ostermayer, MD, d Blanca Steinbrenner, MD, c Christian Apitz, MD, e Matthias Schneider, DVM, f Marcel Suchowski, DVM, g Rita Ruetten, DVM, PhD, h Can Yerebakan, MD, a Johannes Boltze, MD, PhD, b Hatem Elmontaser, MD, c Uygar Yoruker, MD, c Heiner Latus, MD, c Markus Khalil, MD, c Stefan Ostermayer, MD, d Blanca Steinbrenner, MD, c Christian Apitz, MD, e Matthias Schneider, DVM, f Marcel Suchowski, DVM, g Rita Ruetten, DVM, PhD, h

ABSTRACT

Objective: Central pulmonary banding has been proposed as a novel alternative for the treatment of left ventricular dilated cardiomyopathy in children. We sought to investigate the effects of central pulmonary banding in an experimental model of doxorubicin-induced left ventricular dilated cardiomyopathy.

Methods: Four-month-old sheep (n = 28) were treated with intermittent intracoronary injections of doxorubicin (0.75 mg/kg/dose) into the left main coronary artery. A total dose of up to 2.15 mg/kg of doxorubicin was administered until signs of left ventricular dilation with functional impairment occurred by transthoracic echocardiography evaluation. Animals that survived were treated with surgical central pulmonary banding through a left anterior thoracotomy or sham surgery. Transthoracic echocardiography and pressure-volume loop measurements were used to compare left ventricular function preoperatively and 3 months later. Macroscopic and microscopic histologic examinations followed after hearts were harvested.

Results: Nine animals from the central pulmonary banding group and 8 animals from the sham group survived and were included in the final analysis. Both groups showed similar inflammation and fibrosis upon histologic examination consistent with the toxic myocardial effects of doxorubicin. There were no differences in the echocardiographic measurements before central pulmonary banding or sham operation. Baseline measurements before the central pulmonary banding/sham operation were considered as 100%. The central pulmonary banding group had better left ventricular ejection fraction (102.5% ± 21.6% vs 76.7% ± 11.7%, P = .01), with a tendency for smaller left ventricular end-diastolic (101.2% ± 7.4% vs 120.4% ± 10.8%, P = .18) and significantly smaller end-systolic (100.3% ± 12.9% vs 116.5 ± 9.6%, P = .02) diameter of the left ventricle in comparison with the sham animals at 3 months. The end-systolic volume (101.4% ± 31.6% vs 143.4% ± 28.6%, P = .02) was significantly lower in the central pulmonary banding group 3 months postoperatively. Fractional shortening in the long axis (118.5% ± 21.5% vs 85.2% ± 22.8%, P = .016) and short axis (122.5% ± 18% vs 80.9% ± 13.6%, P = .0005) revealed significantly higher values in the central pulmonary banding group. In the conductance catheter measurements, no significant differences were seen between the groups for the parameters of systolic and diastolic function.

From the aChildren’s National Heart Institute, The George Washington University School of Medicine and Health Sciences, Washington, DC; bSchool of Life Sciences, University of Warwick, Coventry, United Kingdom; cPediatric Heart Center Giessen, Justus-Liebig-University, Giessen, Germany; dDepartment of Pediatric Cardiology, University of Aachen, Aachen, Germany; ePediatric Cardiology, University of Ulm, Ulm, Germany; fVeterinary Medicine Clinic for Small Animals, Justus-Liebig-University, Giessen, Germany; gInstitute of Pathology, Faculty of Veterinary Medicine, University Leipzig, Leipzig, Germany; and hFraunhofer-Institute for Cell Therapy and Immunology, Leipzig, Germany. Funded by “Fördergemeinschaft Deutsche Kinderherzzentren e.V.” Germany.

Read at the 98th Annual Meeting of The American Association for Thoracic Surgery, San Diego, California, April 28-May 1, 2018.

Received for publication May 2, 2018; revisions received Dec 21, 2018; accepted for publication Jan 14, 2019; available ahead of print April 8, 2019.

Address for reprints: Can Yerebakan, MD, Department of Cardiovascular Surgery, Children’s National Heart Institute, The George Washington University School of Medicine and Health Sciences, 111 Michigan Ave NW, Washington, DC 20010 (E-mail: cyerebakan@childrensnational.org).

0022-5223/$36.00

Copyright © 2019 by The American Association for Thoracic Surgery
https://doi.org/10.1016/j.jtcvs.2019.01.138
Cardiomyopathies in the pediatric population have an overall incidence of 10 to 12 cases per million. The most common form in children is dilated cardiomyopathy, which occurs in more than 50% of all cardiomyopathies in childhood.1,2 Transplant-free survival in these patients at 1 year and 5 years is reported to be approximately 70% and 60%, respectively.3,4

The clinical presentation of dilated cardiomyopathy is primarily a dilated left ventricular chamber with severely impaired function on echocardiographic evaluation. The underlying etiology may be acute or chronic myocarditis, metabolic or neuromuscular disorders, or noncompaction or idiopathic cardiomyopathy.2,3,5 Left ventricular dysfunction and dilation are usually accompanied by a mild to moderate degree of mitral regurgitation in the early phase. The right ventricle is mostly spared and exhibits milder dysfunction.6

Although conservative medical heart failure therapy may be initiated, further decline in left ventricular function is not rare, and end-stage heart failure may ensue rapidly, requiring mechanical ventilation and inotropic support. However, in severe cases mechanical circulatory support or ultimately heart transplantation will be needed. Mechanical circulatory support for children as a bridge-to-heart transplantation bears substantial potential for severe complications, such as coagulation disorder, embolic insult, infection, and death.7 Studies continue to determine solutions for the optimal circulatory assistance in the pediatric population. Cardiac transplantation remains the gold standard therapy for end-stage heart failure in the pediatric population. However, the chronic shortage of donor organs hinders a wider application of heart transplantation. Even after a successful heart transplant, the 5-year survival remains at 60%.8 Alternative therapies for the treatment of childhood cardiomyopathy are warranted.

Inspired by the advantageous effects of central pulmonary artery banding (cPAB) for the palliation of l-transposition of the great arteries, the first case report of cPAB in a child with left ventricular cardiomyopathy was published by the Giessen group in 2007.9 The positive midterm results of 12 patients were reported by Schranz and colleagues in 2013.10 The experience with cPAB for left ventricular cardiomyopathy has been reported with promising outcomes in 70 patients worldwide.11 The basis for this approach is treatment of left ventricular cardiomyopathy using cPAB, which leads to pressure overload of the right ventricle that is required to possess near to normal function. An improvement of left ventricular function is observed in most treated children within several months. The underlying mechanism for the improvement of left ventricular function is still unknown. The aim of this experimental study was to investigate the myocardial functional and left ventricular dimensional changes using cPAB in a doxorubicin-induced toxic left ventricular cardiomyopathy in a validated model.12

### MATERIALS AND METHODS

#### Animals and Anesthesia

Animals received humane care in compliance with the Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals in Germany. The study was approved by the authority for animal protection in Hessen, Germany (VS4-19c 20/15 – FU/1023).

This study was carried out with the use of 30 four-month-old domestic sheep (median weight, 29 kg; range, 29-36 kg). Two animals were excluded before the start of the study because of other illnesses.

#### Anesthesia and Mechanical Ventilation

All animals received a 10 to 20 mg/kg ketamine dose, followed by intravenous access through an ear vein. Intubation and mechanical ventilation (Excel 210 SE, Ohmeda-BOC Group, Madison, Wis) were established. Propofol infusion was used for maintenance along with anesthesia using fentanyl (20-50 μg/kg/h) and muscular blockade with pancuronium (0.3 mg/kg/h). Oxygen was added to the respiratory circuit with the aim of achieving a peripheral arterial saturation of greater than 94%. Invasive arterial blood pressure was measured through the side port of the arterial access in the carotid or femoral artery. Peripheral arterial saturation was monitored with a pulse-oximeter in a continuous fashion. Postprocedural buprenorphine (0.01 mg/kg twice daily) was used for analgesia. Cefazolin (25 mg/kg) was used for antibiotic prophylaxis.
Coronary Angiography and Doxorubicin Application

The timeline of the experiments and performed investigations is depicted in Figure 1. Up to 3 intracoronary injections of doxorubicin (each dose 0.75 mg/kg) were administered every 2 to 6 weeks until echocardiographic signs of left ventricular functional impairment and spatial dilation were observed. After detection of left ventricular dysfunction and spatial dilation, surgical pulmonary banding was planned 3 to 4 weeks after the last doxorubicin injection.

For the 2 initial doxorubicin injections, a 5F introducer was inserted into the left carotid artery. For the third injection, the left or right femoral artery was percutaneously cannulated with a 5F introducer. After a 100 IE/kg heparin bolus was administered, a 5F pigtail calibration catheter was advanced into the left ventricle under fluoroscopy, and a standard 1-plane cineventriculography at 25 frames per second was performed (Siemens, Arcadis Avantic, Germany). With lateral imaging, a 5F right Judkins catheter (Infiniti JR4, Cordis, Milpitas, Calif) was used to catheterize the left coronary ostium. Adequate placement of the catheter’s tip was checked with small boluses of contrast media. A constant rate of intracoronary infusion of 0.75 mg/kg doxorubicin-hydrochloride solution (Applichem GmbH, Darmstadt, Germany) diluted in 10 mL of saline was started with a syringe pump and maintained over 10 minutes. Animals were closely monitored in the immediate postoperative period for signs of arrhythmia or ventricular dysfunction.

Hemodynamic Assessment

Transthoracic echocardiography. Transthoracic conventional echocardiography was performed by cardiologists experienced in pediatric and adult echocardiography while the animals were under sedation (or endotracheal intubation if there was a planned heart catheterization). Echocardiography was performed at baseline, before each doxorubicin injection, 2 to 4 weeks after the last doxorubicin injection, before cPAB, and before the explantation procedure. A Phillips (Andover, Mass) CX

**TABLE 1. Hemodynamic characteristics before pulmonary artery banding/sham operation in both groups**

<table>
<thead>
<tr>
<th></th>
<th>Sham</th>
<th>cPAB</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Echo LVEDd</td>
<td>4.13 ± 0.24</td>
<td>4.27 ± 0.19</td>
<td>.45</td>
</tr>
<tr>
<td>Echo LVESd</td>
<td>3.11 ± 0.25</td>
<td>3.37 ± 0.40</td>
<td>.49</td>
</tr>
<tr>
<td>Echo EDV (mL)</td>
<td>75.83 ± 10.22</td>
<td>81.79 ± 8.34</td>
<td>.46</td>
</tr>
<tr>
<td>Echo ESV (mL)</td>
<td>38.74 ± 7.32</td>
<td>47.37 ± 12.69</td>
<td>.46</td>
</tr>
<tr>
<td>Echo EF (%)</td>
<td>48.71 ± 7.78</td>
<td>43.14 ± 10.50</td>
<td>.56</td>
</tr>
<tr>
<td>Heart rate (min⁻¹)</td>
<td>109.43 ± 23.11</td>
<td>143.00 ± 31.79</td>
<td>.30</td>
</tr>
<tr>
<td>ESP (mm Hg)</td>
<td>103.86 ± 21.47</td>
<td>129.67 ± 13.72</td>
<td>.11</td>
</tr>
<tr>
<td>EDP (mm Hg)</td>
<td>9.00 ± 3.41</td>
<td>14.00 ± 3.00</td>
<td>.38</td>
</tr>
<tr>
<td>SW (mL/mm Hg)</td>
<td>4867.29 ± 2101.23</td>
<td>5642.00 ± 793.84</td>
<td>.47</td>
</tr>
<tr>
<td>dp/dtmax (mm Hg × s⁻¹)</td>
<td>1257.14 ± 777.12</td>
<td>1827.67 ± 932.18</td>
<td>.51</td>
</tr>
<tr>
<td>dp/dtmin (mm Hg × s⁻¹)</td>
<td>−2008.86 ± 964.39</td>
<td>−2280.67 ± 575.25</td>
<td>.65</td>
</tr>
<tr>
<td>tau (ms)</td>
<td>63.00 ± 69.42</td>
<td>37.67 ± 10.34</td>
<td>.42</td>
</tr>
<tr>
<td>Ees (mm Hg/mL)</td>
<td>1.10 ± 0.38</td>
<td>1.86 ± 0.23*</td>
<td>.02</td>
</tr>
<tr>
<td>Eed (mm Hg/mL)</td>
<td>0.18 ± 0.06</td>
<td>0.27 ± 0.05</td>
<td>.15</td>
</tr>
</tbody>
</table>

Bold values represent significance (P < .05). Values are presented as mean ± standard deviation. cPAB, Central pulmonary artery banding; LVEDd, left ventricular end diastolic diameter; LVESd, left ventricular end systolic diameter; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction; ESP, end-systolic pressure; EDP, end-diastolic pressure; SW, stroke work; dp/dtmax, maximal slope of systolic pressure increment; dp/dtmin, diastolic pressure decrement; tau, left ventricular diastolic time constant; Ees, slope of end-systolic pressure volume relation; Eed, slope of end-diastolic pressure volume relation.
System equipped with an S8-3 MHz transducer was used for continuous electrocardiogram monitoring of the animals. The animals were anesthetized with intravenous injections of 0.5 mg/kg midazolam and 10 mg/kg ketamine. Oxygen was supplied with a face mask. The animals were placed in ventral recumbency, and wool was clipped between the right fourth and seventh intercostal spaces. All transthoracic echocardiographic measurements included a mean of 3 consecutive beats. Left ventricular dimension measurements were performed using 2-dimensional–guided M-mode on the right parasternal ventricular short-axis view, according to the recommendations of the American Society of Echocardiography. Left ventricular end-systolic and end-diastolic diameters, left ventricular end-systolic and diastolic volumes, and left ventricular ejection fraction (LVEF) were measured, and left ventricular shortening fractions were then calculated in the short-axis and long-axis.

Pressure-volume loop measurements using conductance technique. Indices of left ventricular function using a conductance catheter technique were derived at 2 different time points: (1) before the sham (n = 8) cPAB (n = 9) operations and (2) after the explantation of the hearts at the end of the experimental series. The X-axis shows the different groups. The upper and lower borders of the boxes represent the upper and lower quartiles. The middle horizontal line is the median value. Each measurement is shown as a black dot, and the dots outside of the box and whiskers represent outliers. Percentages above the box plots show the relation of each parameter to the baseline level at before cPAB/sham operation (100%). *P < .05. Blue color: sham group, green color: cPAB group. LVESD, left ventricular end-systolic diameter; LVEDd, left ventricular end-diastolic diameter; LVESV, left ventricular end-systolic volume; LVEDV, left ventricular end-diastolic volume; cPAB, central pulmonary artery banding; LVEF, left ventricular ejection fraction.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Sham (n = 8)</th>
<th>cPAB (n = 9)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVESD (cm)</td>
<td>117 ± 10%</td>
<td>100 ± 13%</td>
<td>.02</td>
</tr>
<tr>
<td>LVEDD (cm)</td>
<td>108 ± 11%</td>
<td>101 ± 7%</td>
<td>.18</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>77 ± 12%</td>
<td>103 ± 22%</td>
<td>.01</td>
</tr>
<tr>
<td>LVEDV (mL)</td>
<td>143 ± 29%</td>
<td>101 ± 32%</td>
<td>.02</td>
</tr>
<tr>
<td>LVESV (mL)</td>
<td>120 ± 30%</td>
<td>103 ± 18%</td>
<td>.09</td>
</tr>
</tbody>
</table>

FIGURE 2. A and B, Transthoracic echocardiographic measurements of the sham and cPAB groups before the explantation of the hearts at the end of the experimental series. The X-axis shows the different groups. The upper and lower borders of the boxes represent the upper and lower quartiles. The middle horizontal line is the median value. Each measurement is shown as a black dot, and the dots outside of the box and whiskers represent outliers. Percentages above the box plots show the relation of each parameter to the baseline level at before cPAB/sham operation (100%). *P < .05. Blue color: sham group, green color: cPAB group. LVESD, left ventricular end-systolic diameter; LVEDD, left ventricular end-diastolic diameter; LVESV, left ventricular end-systolic volume; LVEDV, left ventricular end-diastolic volume; cPAB, central pulmonary artery banding; LVEF, left ventricular ejection fraction.
start of doxorubicin injection into the coronary arteries and (2) before the
eclaration of the hearts 3 months after the cPAB procedure. Assessment
of left ventricular intrinsic myocardial function by analysis of pressure-
volume (PV) loops was performed using cardiac function hardware
(INCA, CD Leycom, Hengelo, The Netherlands) and software package
version 3.8 (2008; CD Leycom). To acquire PV loops, a 4F conductance
catheter with 12 electrodes and integrated manometer (41063-PN, CD Ley-
com) was placed in the ventricle via left carotid artery cannulation and the
ascending aorta. A gradual reduction in ventricular volume (preload reduc-
tion) was induced by occlusion of the inferior cava vein using an 8/2 Fo-
gury catheter (Edward Lifesciences GmbH, Unterschleissheim, Germany)
that was introduced through the right internal jugular vein. Recordings
were made during at least 3 maneuvers in each subject. If ectopic beats
occurred during the preload reduction, the recording was repeated to obtain
at least 2 acceptable measurements. All measurements were performed
during short periods of suspended ventilation at end expiration. Heart
rate, end-diastolic pressure, end-systolic pressure, and maximal rate of
pressure change (maximal slope of systolic pressure increment [dp/dtmax])
were analyzed. Stroke work was calculated as the area enclosed by the PV
loop. Indices of load-independent systolic and diastolic left ventricular
function were obtained from PV loops recorded during preload reduction
by the slope of the end-systolic and end-diastolic PV relation. The time
constant of relaxation (τ), reflecting the early active relaxation process,
was calculated as the time constant of the monoexponential pressure decay
during isovolumetric relaxation. The isovolumetric period was defined as
the period between the time point of maximal slope of diastolic pressure
decrement (dp/dtmin) and the time point at which dp/dt reached 10% of
the dp/dtmax value.

Central pulmonary artery banding/sham procedure.
After the documentation of a dilated cardiomyopathy of the left ventricle,
surgical pulmonary artery banding (PAB) was performed in the cPAB
group. This was achieved by banding of the pulmonary trunk with a 2-
mm–wide Dacron band via a left anterior thoracotomy through the fifth
or sixth intercostal space. The degree of the pulmonary stenosis was grad-
ually adjusted by direct intraventricular measurements with a pressure tip
catheter and an elevation of the systolic right ventricular maximal pressure
above the baseline level. When the desired pressure level was reached, the 2
ends of the Dacron band were fixed using 2 stitches through both ends of the band with 5-0 Prolene. The band was fixed on
the wall of the pulmonary trunk using single 5-0 Prolene stitches on each
side to prevent inadvertent sliding of the band toward the pulmonary bifur-
cation. The sham animals received a left anterior thoracotomy through the fifth or sixth intercostal space with pericardial opening only.

Descriptions of the macroscopic organ inspection and microscopic investi-
gation of inflammatory cell load and fibrosis are available in the Appendix E1.

Statistics
Data were analyzed for normal distribution using the Kolmogorov–
Smirnov test. Pairwise comparison was performed using a t test for nor-
mally distributed data and the Mann–Whitney U test for not normally
distributed data. Comparison between more than 2 groups was performed
using 1-way analysis of variance testing followed by post hoc correction
using Tukey’s test. Statistically significant differences were indicated by
single asterisks (*P < .05).

RESULTS
Survival
Two animals were excluded from the study because of other
illnesses before the cPAB. Mortality occurred in 8
of the 11 cases before the cPAB. Eight animals died during
the period between the start of the doxorubicin injections
and the PAB procedure (3 animals during anesthesia appli-
cation, 1 animal had malignant arrhythmia during cardiac
catheterization, and 4 animals after anesthesia for the echo-
cardiography and cardiac catheterization due to unknown
postprocedural reasons in the barn).

There were 3 operative deaths during or after cPAB or
sham operation (1 animal from the PAB group and 2 ani-
imals from the sham group; 1 due to surgical bleeding
from the aorta, and 2 due to hemodynamic deterioration,
1 early and 1 two weeks after the operation, respectively).
Nine animals in the cPAB group and 8 animals in the
sham group with similar weights survived and were
included in the final analyses.

Myocardial Function and Dimensions
Echocardiographic results. There were no differences in the
echocardiographic measurements before the index oper-
ation of cPAB or sham operation between the 2 groups.
These measurements were considered as the baseline level
(100%) (Table 1). The subsequent echocardiographic re-
sults were calculated as percentages of the baseline before
the explantation of the hearts after a median follow-up of
3 months. The absolute values are presented in median
and interquartile ranges in Figure 2, A and B.

Before the explantation of the hearts, the cPAB group had
better LVEF (102.5% ± 21.6% vs 76.7% ± 11.7%,
P = .0197), with similar left ventricular end-diastolic vol-
umes (101.2% ± 7.4% vs 120.4% ± 10.8%, P = .1774)
and significantly smaller end-systolic diameters
(100.3% ± 12.9% vs 116.5% ± 9.6%, P = .021)
compared with the sham animals before heart explantation.
The left ventricular end-systolic volume (101.4% ± 31.6% vs
143.4% ± 28.6%, P = .0214) was lower in the cPAB
group, and the left ventricular end-diastolic volume
(103.3% ± 18% vs 120.4% ± 29.5%, P = .092) was
similar between the groups. There were significantly higher
values for fractional shortening in the long axis

![VIDEO 1. The transthoracic echocardiographic assessment of a representa-
tive animal from the cPAB group at 3 different time points is shown: (1) at
baseline before the doxorubicin treatment; (2) after doxorubicin treatment
before cPAB; and (3) 3 months after cPAB. Video available at: https://
FIGURE 3. A and B, Conductance catheter measurements with PV loop assessment of the sham and cPAB groups before the explantation of the hearts at the end of the experimental series. The X-axis shows the different groups. The upper and lower borders of the boxes represent the upper and lower quartiles. The middle horizontal line is the median value. Each measurement is shown as a black dot, and the dots outside of the box and whiskers represent outliers. Percentages above the box plots show the relation of each parameter to the baseline level at before cPAB/sham operation (100%). *P < .05. Blue color: sham group, green color: cPAB group. LVEDP, Left ventricular end-diastolic pressure; LVESP, left ventricular end-systolic pressure; cPAB, central pulmonary artery banding; dp/dt max, maximal slope of systolic pressure increment; dp/dt min, diastolic pressure decrement; Eed, slope of end-diastolic pressure volume relation; Ees, slope of end-systolic pressure volume relation.
(118.5% ± 21.5% vs 85.2% ± 22.8%, P = .0164) and short axis (122.5% ± 18% vs 89.9% ± 13.6%, P = .0005) in the cPAB group (Figure 2, A and B). The echocardiographic findings of 1 representative animal from the cPAB group throughout the experiments are presented in Video 1.

Pressure-volume loop measurements
There were no differences between the groups in the baseline PV loop measurements. During the PV loop assessments before explantation, we noted a lower heart rate in the cPAB group (58.7 ± 5.5 beats/min vs 72.6 ± 4.2 beats/min, P = .002). No significant differences were seen for the parameters of systolic function, such as dp/dt\(_{\text{max}}\), stroke work, and end-systolic elastance and left ventricular end-systolic pressure (84.9 ± 14.3 mm Hg vs 100.4 ± 14.7 mm Hg, P = .0636). With regard to diastolic functional properties, the dp/dt\(_{\text{min}}\) was similar in both groups (91.2 ± 24.9 mm Hg/s vs 128.8 ± 43.5 mm Hg/s, P = .0591). Likewise, end-diastolic elastance and diastolic time constant end-systolic and end-diastolic pressures were similar in the cPAB and sham groups (Figure 3, A and B, and Figure E1).

Microscopic examinations
The area of fibrosis and the inflammatory cell count in both the cPAB and sham groups did not differ significantly in the Picrosirius red and hematoxylin-eosin staining, respectively. There was a tendency for higher values of fibrosis area and inflammatory cell count in the experimental cohort than in hearts from healthy controls (Figure 6, A and B).

DISCUSSION
CPAB was first implemented to restrict excessive pulmonary blood flow in cases with left-to-right intracardiac shunting. Over the years, several other applications were introduced.
In 2007, the Giessen group from Germany reported the first application of cPAB for the treatment of left ventricular cardiomyopathy in a pediatric patient. Further data have been introduced from the Giessen group as well as others over the past several years. A summary of the worldwide experience of cPAB for the treatment of left ventricular cardiomyopathy was most recently reported by Schranz and colleagues.

This is the first experimental series worldwide to use surgical cPAB treat toxic dilated cardiomyopathy in a sheep model. Other groups have published the method of intracoronary doxorubicin infusion with successful creation of a dilated left ventricle with reduced function. The standard technical approach of the Giessen group was replicated in this experimental work for surgical cPAB with direct intracardiac pressure measurements for pulmonary band adjustment. In our series, the intracoronary application of doxorubicin led to left ventricular dilation and reduced left ventricular function with a reduction in LVEF and fractional shortening on transthoracic echocardiography.

After surgical cPAB, we observed significantly lower left ventricular end-systolic diameters and volumes before explantation of the hearts. The cPAB group had greater LVEF and short- and long-axis fractional shortening 3 months after the banding procedure. The findings should be accepted in the context of a lower heart rate in the cPAB group before the explantation of the hearts (58.7 ± 5.5 beats/min vs 72.6 ± 4.2 beats/min, P = .002). The observed lower heart rate can be interpreted as a sign of less pronounced heart failure in the cPAB group, because a higher heart rate is known to be associated with a worse prognosis in the context of adult chronic heart failure. The lower heart rate may have affected our echocardiographic findings; however, no animal had tachycardia per the definition, so the effect of the different heart rates between the groups on the echocardiographic results is expected to be limited. Conductance catheter measurements with the assessment of PV loops failed to demonstrate any significant differences between the groups, but there was a trend to a lower end-systolic pressure in the left ventricle of the cPAB group (P = .06). The reasons for this discrepant finding may be that we had relatively significant outliers in the PV loop measurements in both groups, the duration of 3 months may not be long enough to see a significant improvement in the intrinsic contractile properties of the ventricle, and the cardiomyopathy observed in this study had a toxic nature with a different cause than dilated cardiomyopathy in childhood.

The outcomes of infants and young children who undergo cardiac transplantation for dilated cardiomyopathy worsen with the severity of left ventricular dilation. In the setting of pressure overload of the right heart, one of the potential mechanisms of reduced left ventricular dimensions and

![FIGURE 5. Macroscopic appearance of the heart of 1 representative animal from the cPAB group. A, Entire heart showing the main pulmonary artery (note the banding) and the aorta (probes). B, Sections at 3 different levels of the main pulmonary artery (note the narrowing at the banding site). C, Midventricular cross-section of the left and right ventricular cavities (note the right ventricular hypertrophy). D, Left ventricular cavity, septal left ventricular surface, and right ventricular cavity (longitudinal section) from left to right.](image-url)
**FIGURE 6.** A, Inflammatory cell count (top) and fibrosis area (bottom) in the healthy control animals (yellow), sham group (blue), and cPAB (green) group in locations A and B separated in 4 different levels of the myocardium. *Light yellow:* close to epicardium, *yellow:* central myocardium, *pink:* close to endocardium, *white:* average value of all 3 levels. The *X-axis* shows the different groups. The *upper* and *lower* borders of the *boxes* represent the upper and lower quartiles. The *middle horizontal line* is the median value. Each measurement is shown as a *black dot*, and the *dots* outside of the *box* and *whiskers* represent outliers. B, Picrosirius and hematoxylin–eosin staining in healthy animals (left) and cPAB group (right). Inflammatory changes and increased fibrosis were seen in both experimental groups (sham and cPAB), but more prominently than in the healthy controls. *HPF,* High-power field.
improved left ventricular function might be the leftward shift of the interventricular septum. This mechanism and its mechanical effects on the left ventricular function have been described in patients with pulmonary hypertension.\textsuperscript{17} We observed a septal shift in the cPAB group in the echocardiographic evaluations, but the extent was not quantified to serve as a reliable marker for the improved left ventricular dimensions in our experimental model. The functional effects of septal shift on the clinical application of cPAB for left ventricular cardiomyopathy have been shown.\textsuperscript{18} Furthermore, the septal shift may change the shape of the left ventricle and reduce the amount of mitral regurgitation, with the result of optimizing the volume overload of the left ventricle. The favorable change in the Frank-Starling curve and the reduction in left ventricular preload and end-diastolic/end-systolic filling pressures may enable a more favorable hemodynamic state. An enhanced right ventricular function has been shown to contribute to left ventricular function in the setting of cardiac resynchronization therapy in adults.\textsuperscript{19} The reduced preload conditions for the left ventricle could not be clearly demonstrated in our experimental series because the end-diastolic and end-systolic pressures were similar between the groups in the conductance catheter measurements ($P = .29$ and .06,  

\begin{figure}
\centering
\includegraphics[width=\textwidth]{image.png}
\caption{Four-month-old sheep ($n = 28$) were treated with intermittent intracoronary injections of doxorubicin (0.75 mg/kg/dose) into the left main coronary artery until functional impairment and spatial dilation in the transthoracic echocardiography. Animals underwent a sham/cPAB procedure with hemodynamic assessment using transthoracic echocardiography and PV loop assessment before harvesting the hearts. Animals that underwent cPAB showed significant improvement in left ventricular dimensions and volume (LVESD, LVESV) and left ventricular function (FS, LVEF) in comparison with the sham group before harvesting the hearts for histologic investigations. \textit{LVESD}, left ventricular end-systolic diameter; \textit{LVESV}, left ventricular end-systolic volume; \textit{LVEF}, left ventricular ejection fraction; \textit{FS}, fractional shortening; \textit{Doxo}, doxorubicin; \textit{cPAB}, central pulmonary artery banding; \textit{TTE}, transthoracic echocardiography; \textit{PV}, pressure-volume.}
\end{figure}
respectively). In contrast, in the cPAB group, the left ventricular end-systolic diameter and volume were significantly lower in comparison with the sham group without cPAB. Significantly higher LVEF and fractional shortening were also noted in the cPAB group.

Another potential mechanism that is proposed for the long-term improvement of left ventricular function by cPAB is the considerably higher regenerative capacity of the young heart. The regenerative capacity of the heart decreases with age, and strategies that rely on the regenerative potential of the young myocardium are promising.20 A stimulation of resident intracardiac stem cells and stem cell recruitment from the periphery may contribute to the improvement of left ventricular function.21,22 In our study, we did not detect any significant differences in the amount of fibrosis or inflammation within the cPAB and sham groups. This finding reveals similar effects of doxorubicin treatment on the left ventricular myocardium in both experimental groups.

We have observed a significant hypertrophy of the right ventricle in the macroscopic examinations as expected after effective PAB. Existing data describe a biological crosstalk between the right and left ventricles that may lead to the improvement of left ventricular function.23,24 Whether the Anrep effect, which leads to physiologically enhanced right ventricular contractility25 when the afterload increases following the Frank-Starling law, conveys its effect to the left side of the heart through a biological interaction (ie, the change in biventricular gene expression) remains speculative but possible.26

Study Limitations

Doxorubicin-induced cardiomyopathy leads to similar histologic changes as in dilated cardiomyopathy with degeneration of cardiomyocytes, vasculopathy, inflammatory infiltrates, and replacement fibrosis. However, the experimental animal model cannot fully simulate the clinical situation of a dilated cardiomyopathy in early childhood.

However, an in-depth analysis (ie, with immunohistochemistry) was not used; therefore, those subtle changes may not have been detected. This aspect is a significant limitation of our study that might have shown the effects of the PAB on the cellular level.

Adjunct medical heart failure treatment was not performed in this study, so we have likely not used the full potential of cPAB in these experiments. In the clinical setting, patients who undergo cPAB for left ventricular cardiomyopathy receive advanced intensive medical heart failure treatment after the procedure.27 The Giessen group reported that their advanced heart failure therapy may aid in the recovery and reverse remodeling of the left heart.28 In our experimental setting, cardiomyopathy was caused by a toxic cytostatic agent and is not comparable to the etiology of left ventricular cardiomyopathy in the clinical setting and experience. Furthermore, none of the animals received medical heart failure treatment postoperatively, so any potential beneficial effect is missing in this experimental series.

Right ventricular function and mitral regurgitation were not quantitated in our study; however, qualitative echocardiography did not reveal severe right ventricular dysfunction or mitral regurgitation in any of the animals. The heart rate in the cPAB group was lower before heart explantation. No animal was in a tachycardia state; nonetheless, our echocardiographic results, which may have been influenced by heart rate, should be accepted with caution.

CONCLUSIONS

cPAB in the experimental setting of toxic cardiomyopathy seems to improve only the echocardiographic left ventricular function and reduces left ventricular dimensions in the medium-term follow-up without an effect on the PV loop assessments (Figure 7). Whether the indication for a cPAB can be extended to further etiologies that lead to left ventricular functional compromise with spatial dilation and to older patients with left ventricular failure can be answered only with further detailed experimental work that can elucidate the underlying molecular mechanisms of this novel strategy. In addition, clinical application of this simple surgical technique, with low postoperative risk, in prospective, randomized multicenter studies for different etiologies may enable further understanding of its role in the treatment of dilated left ventricular cardiomyopathy.

Webcast

You can watch a Webcast of this AATS meeting presentation by going to: https://aats.blob.core.windows.net/media/18May01/28DE%20Cardiac%20Surgery%20Forum/S74_6_webcast_080258710.mp4.

Conflict of Interest Statement

Authors have nothing to disclose with regard to commercial support.

The authors thank Dr Christa Tandi and Dr Alf Theisen from the J. W. Goethe University Frankfurt, Germany, for the veterinary support during the experimental series, and Katherine Klein for language editing of the manuscript.
References


14. Limlaw DS, McGuirk SP, Balmer C, Langley SM, Griselli M, Stümpner O, et al. Intention-to-treat analysis of pulmonary artery banding in conditions with a correctible anatomic lesion, options are limited to medical or by surgically addressing the lesion. In the absence of a correctible anatomic lesion, options are limited to medical or device support and ultimately transplantation. Devising and testing novel surgical approaches to improve these outcomes are of intrinsic scientific merit, and this article is a laudable step in that direction.


Key Words: cardiomyopathy, heart failure, pulmonary artery banding, left ventricle

Discussion

Dr Ram Kumar Subramanyan (Los Angeles, Calif). Yerebakan and colleagues provide valuable animal model data on the benefit of CPAB after doxorubicin-induced cardiac dysfunction. The concept is of significance to the scientific community, today’s presentation was excellent, and the manuscript you sent me is absolutely well written. Congratulations on a job well done.

Dilated cardiomyopathy is a vexing problem in children and has limited surgical options. When there is a correctible congenital anatomic defect, the outcome can be impacted by surgically addressing the lesion. In the absence of a correctible anatomic lesion, options are limited to medical or device support and ultimately transplantation. Devising and testing novel surgical approaches to improve these outcomes are of intrinsic scientific merit, and this article is a laudable step in that direction.

Cam, I have a few questions for you. You rightly point out in your article the lack of a quality animal model of dilated cardiomyopathy. Your study was carried out in a doxorubicin-induced cardiac dysfunction model. Could you tell us why you believe this is a good surrogate for clinical dilated cardiomyopathy? In particular, have you done studies to show that there is thinning of the ventricular wall or magnetic resonance imaging to suggest that this mimics clinical dilated cardiomyopathy or develop mitral regurgitation, for example?
Dr Can Yerebakan (Washington, DC). I have been working for the last 10 years with animal models in Germany and looked for a valid model for dilated cardiomyopathy that is similar to the clinical scenario of patients we see in the neonatal phase. I then excluded all models with volume overload, pressure overload, which would not give us the features of a dilated cardiomyopathy in a short time period. Therefore, I searched for another model, and this is a toxic model, which actually disturbs the myocardial integrity similar to an acute myocarditis or idiopathic cardiomyopathy in childhood.

Borenstein and colleagues from France used this model and were able to show that doxorubicin leads to a dilated cardiomyopathy in a short time period of many weeks, and therefore I thought this model was the best one to choose from.

To your second question, we were able to show dilation of the left ventricular chamber. Unfortunately, these figures are not in the article but I will add them, but we showed spatial dilation and functional myocardial impairment. There was no myocardial thinning, so the measurements of the left ventricular wall in comparison with sham animals were not different. We were able to show right ventricular hypertrophy and left ventricular fibrosis, but no wall thinning. This is the answer for your second question.

Dr Subramanyan. In your discussion, you speculate on what the mechanisms of the observed benefit could be. The big advantage of an animal model is being able to ask mechanistic questions. So, do you have an idea or have you experimentally tested any of these hypotheses in your model? In particular, if I read your data correctly, the predominant benefit of PAB, in my opinion, is reduction in the deterioration of heart function, which is certainly different from improvement in deteriorated heart function. What do you think?

Dr Yerebakan. This is extremely interesting. I am convinced by this simple surgical method, because it has already been used clinically, and I was looking for mechanisms, as you correctly raise, possible mechanisms to explain the effect.

Just shortly for the sake of time, it might be a leftward shift of the interventricular septum with reduction of the mitral regurgitation. We didn’t have a lot of significant mitral regurgitation in our animals, and I don’t think this would be the leading mechanism in these experiments. Leftward shift of the interventricular septum leads to a reduction of left ventricular dimensions and prevention of a deterioration of left ventricular function before an irreversible loop of dilation with following occurs. Additionally, the preload reduction of the left ventricle might have contributed to favorable hemodynamics after pulmonary artery banding.

Second mechanism might be a regenerative pathway following PAB with stimulation of resident or peripheral stem cells with induction of a reverse remodeling of the left ventricle. The time period in this experiment might be too short to speculate that this is the mechanism.

And the third might be the so-called Anrep effect, which was described in 1912. That implies an afterload increase of the left or right ventricle with better contractility.

Dr Tomasz Timek (Grand Rapids, Mich). We would like to cut you off here a bit, and I appreciate the discussion, but before we let you off the hook, are you trading left ventricular dysfunction for right ventricular dysfunction, yes or no?

Dr Yerebakan. We are treating left ventricular dysfunction.

Dr Timek. What happens to the right side?

Dr Yerebakan. I cannot answer with the data what happens to the right side, but I know from my previous experiments the chronic afterload increase of the right ventricle leads to fibrosis. But in these patients clinically, we partially de-band the patients at midterm follow-up to prevent right ventricular dysfunction.
APPENDIX E1. MACROSCOPIC INVESTIGATION
Hearts including the epicardium and pericardium were visually inspected for any abnormalities. The heart was weighted, and the following dimensions were measured: outer circumference, height of auricular and atrial facies, size of the left and right atria (length × width × height), and extension of the left and right ventricle (length × width).

The vessels were also prepared and cut to assess the maximal and minimal outer and inner diameters of the brachiocephalic artery, as well as outer and inner diameters of the right pulmonary artery, superior (cranial) vena cava, and inferior (caudal) vena cava. The aorta was assessed at 3 different locations: its origin, in the middle (2 cm from the origin), and at the cut (~4 cm from origin). Maximal and minimal outer and inner aortic diameters were measured. The same procedure was performed for the pulmonary trunk. Maximal and minimal outer and inner diameters were also measured for the left coronary artery. The left coronary artery is more prominent in ruminants than the right coronary artery for which outer and inner diameters were also measured.

The heart was then opened, and maximal and minimal atrial wall widths as well as lengths of the left and right atrioventricular ring were measured. The maximal dimensions (length, width, height) of the sinus venarum cavarum were measured on the right atrium. Atria were dissected, and the weight of both ventricles including the septum was measured. Ventricles and septum were then separated. Weight, inner dimensions (length × width), and wall widths were measured. The latter were measured on the inflow and outflow areas of each ventricle at the heart’s base, middle, and apex, respectively. Dimensions of major papillary muscles (length, width, height) and septal wall width on the base, middle, and apex were also assessed.

All investigations were carried out by a board-certified veterinary pathologist. Because a stenosis was clearly visible on the pulmonary trunk of banded animals, but absent in sham animals, macroscopic assessment could not be carried out in a blinded fashion.

MICROSCOPIC INVESTIGATION OF INFLAMMATORY CELL LOAD AND FIBROSIS
Small tissue blocks were gained from 2 locations in the left ventricle, that is, from the facies auricularis close to the subauricular (location A) and subatrial papillary muscle (location B), respectively. Tissue samples were embedded in Paraplast (Vogel, Gießen, Germany) using a Hypercenter XP automated embedding device (Shandon, Frankfurt, Germany). According to the manufacturer’s instructions, the tissue was cut into 4-μm slices using a sledge microtome (Reichert-Jung, Vienna, Austria). Slices were stained with hematoxylin–eosin (immune cell invasion) or Picrosirius red (fibrosis) according to standard procedures. Images were taken using a DP-26 camera connected to a BH-2 microscope (both Olympus, Hamburg, Germany) and stored digitally. All analyses were performed using the cellSens Dimension software (Olympus). Nine randomly chosen high-power field (HPFs) images were assessed. Three HPFs each from an area close to the epicardium, central, and close to the endocardium were evaluated.

Inflammatory cell load (mononuclear cells and neutrophils) was measured by counting the number of cells in each HPF and categorized using the following score: 0 (0-5 cells/HPF), 0.5 (6-25 cells), 1.0 (26-45 cells), 1.5 (46-65 cells), 2.0 (66-85 cells), 2.5 (86-105 cells), and 3.0 (>105 cells). For fibrosis assessment, images were optimized for contrast using the embedded software tools. Collagenous fibers (fibrosis) appear in bright red to red, depending on their disposition density in Picrosirius red staining. Therefore, color variability was compensated by adjusting the hue, saturation, and value threshold of each image. Fibrosis area (μm²/HPF) was then automatically assessed by the software. Minimal size of included objects was set to 100 pixels. Inflammatory cell scores and fibrotic area were averaged for the 3 HPFs observed in each area. Microscopic investigations were carried out by a board-certified veterinary pathologist who was blinded to the experimental groups.
FIGURE E1. Representative PV loop recordings from the sham (A) and cPAB (B) groups in comparison. The volume is depicted in the x-axis, and the pressure is depicted in the y-axis. Each of the loops represent 1 cardiac cycle during preload reduction maneuvers. The slopes of end-diastolic (Eed) and end-systolic (Ees) PV relations can be calculated from the green and blue curves, respectively.

TABLE E1. Macroscopic dimensions of the right heart after explantation

<table>
<thead>
<tr>
<th></th>
<th>Sham</th>
<th>cPAB</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Atrium</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial volume</td>
<td>43.63 ± 9.26</td>
<td>62.04 ± 36.34</td>
<td>.17</td>
</tr>
<tr>
<td>(external dimensions, cm³)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial volume</td>
<td>1.56 ± 0.37</td>
<td>2.62 ± 1.90</td>
<td>.14</td>
</tr>
<tr>
<td>(sinus venarum cavarum, cm³)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minimal atrial wall width (cm)</td>
<td>0.10 ± 0.00</td>
<td>0.17 ± 0.05</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Maximal atrial wall width (cm)</td>
<td>0.41 ± 0.09</td>
<td>0.53 ± 0.07</td>
<td>&lt;.05</td>
</tr>
<tr>
<td>Length atrioventricular ring (cm)</td>
<td>8.61 ± 1.25</td>
<td>9.44 ± 0.90</td>
<td>.13</td>
</tr>
<tr>
<td><strong>Ventricle, inflow area</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wall width (cm)</td>
<td>0.50 ± 0.05</td>
<td>0.59 ± 0.19</td>
<td>.12</td>
</tr>
<tr>
<td>Wall width, basis</td>
<td>0.47 ± 0.10</td>
<td>0.53 ± 0.10</td>
<td>.20</td>
</tr>
<tr>
<td>Wall width, center</td>
<td>0.39 ± 0.12</td>
<td>0.47 ± 0.12</td>
<td>.19</td>
</tr>
<tr>
<td><strong>Ventricle, outflow area</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wall width (cm)</td>
<td>0.47 ± 0.11</td>
<td>0.53 ± 0.10</td>
<td>.20</td>
</tr>
<tr>
<td>Wall width, basis</td>
<td>0.47 ± 0.11</td>
<td>0.51 ± 0.19</td>
<td>.56</td>
</tr>
<tr>
<td>Wall width, center</td>
<td>0.31 ± 0.09</td>
<td>0.48 ± 0.25</td>
<td>.09</td>
</tr>
<tr>
<td><strong>Large papillary muscle</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Volume (cm³)</td>
<td>0.59 ± 0.27</td>
<td>1.04 ± 0.58</td>
<td>&lt;.05</td>
</tr>
</tbody>
</table>

Bold indicates $P < .05$. cPAB, Central pulmonary artery banding.
### TABLE E2. Macroscopic dimensions of the left heart after explantation

<table>
<thead>
<tr>
<th></th>
<th>Sham</th>
<th>cPAB</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Atrium</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial volume (external dimensions, cm³)</td>
<td>66.3 ± 56.2</td>
<td>64.9 ± 18.8</td>
<td>.95</td>
</tr>
<tr>
<td>Minimal atrial wall width (cm)</td>
<td>0.18 ± 0.07</td>
<td>0.18 ± 0.07</td>
<td>1.00</td>
</tr>
<tr>
<td>Maximal atrial wall width (cm)</td>
<td>0.51 ± 0.14</td>
<td>0.54 ± 0.07</td>
<td>.53</td>
</tr>
<tr>
<td>Length atrioventricular ring (cm)</td>
<td>7.21 ± 0.83</td>
<td>7.78 ± 0.89</td>
<td>.18</td>
</tr>
<tr>
<td><strong>Ventricle, inflow area</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wall width, basis (cm)</td>
<td>1.17 ± 0.17</td>
<td>1.19 ± 0.18</td>
<td>.79</td>
</tr>
<tr>
<td>Wall width, center (cm)</td>
<td>1.03 ± 0.15</td>
<td>0.99 ± 0.14</td>
<td>.52</td>
</tr>
<tr>
<td>Wall width, apex (cm)</td>
<td>0.71 ± 0.20</td>
<td>0.79 ± 0.17</td>
<td>.38</td>
</tr>
<tr>
<td><strong>Ventricle, outflow area</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wall width, basis (cm)</td>
<td>1.20 ± 0.28</td>
<td>1.18 ± 0.17</td>
<td>.84</td>
</tr>
<tr>
<td>Wall width, center (cm)</td>
<td>0.99 ± 0.18</td>
<td>1.06 ± 0.24</td>
<td>.51</td>
</tr>
<tr>
<td>Wall width, apex (cm)</td>
<td>0.92 ± 0.18</td>
<td>0.90 ± 0.15</td>
<td>.78</td>
</tr>
<tr>
<td>Minimal wall width (overall, cm)</td>
<td>0.48 ± 0.14</td>
<td>0.47 ± 0.16</td>
<td>.88</td>
</tr>
<tr>
<td><strong>Papillary muscle volumes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musculus papillaris subauricularis (cm³)</td>
<td>2.10 ± 0.93</td>
<td>2.58 ± 0.96</td>
<td>.30</td>
</tr>
<tr>
<td>M papillaris subatrialis (cm³)</td>
<td>2.43 ± 1.46</td>
<td>2.76 ± 1.11</td>
<td>.61</td>
</tr>
</tbody>
</table>

*PAB, Central pulmonary artery banding.*

### TABLE E3. Macroscopic dimensions of the septum

<table>
<thead>
<tr>
<th></th>
<th>Sham</th>
<th>cPAB</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wall width basis (cm)</td>
<td>1.19 ± 0.28</td>
<td>1.21 ± 0.32</td>
<td>.88</td>
</tr>
<tr>
<td>Wall width center (cm)</td>
<td>1.02 ± 0.11</td>
<td>1.18 ± 0.32</td>
<td>.20</td>
</tr>
<tr>
<td>Wall width apex (cm)</td>
<td>0.98 ± 0.04</td>
<td>1.09 ± 0.43</td>
<td>.46</td>
</tr>
</tbody>
</table>

*cPAB, Central pulmonary artery banding.*
<table>
<thead>
<tr>
<th>TABLE E4. Macroscopic dimensions of large vessels</th>
<th>Sham</th>
<th>cPAB</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Truncus pulmonalis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inner diameter at basis min/max (cm)</td>
<td>1.08 ± 0.23/1.23 ± 0.23</td>
<td>1.27 ± 0.23/1.69 ± 0.27</td>
<td>.09/.01</td>
</tr>
<tr>
<td>Outer diameter at basis min/max (cm)</td>
<td>1.53 ± 0.23/1.70 ± 0.22</td>
<td>1.84 ± 0.29/2.28 ± 0.31</td>
<td>&lt;.05/&lt;.01</td>
</tr>
<tr>
<td>Inner diameter at center min/max (cm)</td>
<td>1.00 ± 0.13/1.21 ± 0.15</td>
<td>0.74 ± 0.21/0.98 ± 0.20</td>
<td>&lt;.01/.02</td>
</tr>
<tr>
<td>Outer diameter at center min/max (cm)</td>
<td>1.50 ± 0.12/1.73 ± 0.12</td>
<td>1.51 ± 0.40/1.89 ± 0.73</td>
<td>.94/.55</td>
</tr>
<tr>
<td>Inner diameter at top* min/max (cm)</td>
<td>0.99 ± 0.20/1.18 ± 0.16</td>
<td>0.74 ± 0.25/1.12 ± 0.32</td>
<td>&lt;.05/.65</td>
</tr>
<tr>
<td>Outer diameter at top* min/max (cm)</td>
<td>1.40 ± 0.21/1.58 ± 0.20</td>
<td>1.19 ± 0.33/1.53 ± 0.35</td>
<td>.13/.77</td>
</tr>
<tr>
<td><strong>Aorta</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inner diameter at basis min/max (cm)</td>
<td>0.74 ± 0.15/1.30 ± 0.23</td>
<td>0.78 ± 0.28/1.23/0.14</td>
<td>.76/.48</td>
</tr>
<tr>
<td>Outer diameter at basis min/max (cm)</td>
<td>1.33 ± 0.16/1.78 ± 0.20</td>
<td>1.37 ± 0.21/1.77 ± 0.12</td>
<td>.71/.89</td>
</tr>
<tr>
<td>Inner diameter at center min/max (cm)</td>
<td>0.80 ± 0.10/1.32 ± 0.17</td>
<td>0.78 ± 0.24/1.26 ± 0.12</td>
<td>.81/.36</td>
</tr>
<tr>
<td>Outer diameter at center min/max (cm)</td>
<td>1.27 ± 0.14/1.74 ± 0.19</td>
<td>1.37 ± 0.18/1.71 ± 0.09</td>
<td>.21/.65</td>
</tr>
<tr>
<td>Inner diameter at top y min/max (cm)</td>
<td>0.79 ± 0.12/1.20 ± 0.24</td>
<td>0.73 ± 0.19/1.22 ± 0.11</td>
<td>.46/.80</td>
</tr>
<tr>
<td>Outer diameter at top y min/max (cm)</td>
<td>1.30 ± 0.20/1.66 ± 0.24</td>
<td>1.32 ± 0.15/1.72 ± 0.13</td>
<td>.80/.48</td>
</tr>
<tr>
<td><strong>Truncus brachiocephalicus</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inner diameter min/max (cm)</td>
<td>0.59 ± 0.11/0.87 ± 0.17</td>
<td>0.43 ± 0.10/0.93 ± 0.21</td>
<td>&lt;.01/.47</td>
</tr>
<tr>
<td>Outer diameter min/max (cm)</td>
<td>1.01 ± 0.12/1.34 ± 0.20</td>
<td>0.86 ± 0.16/1.33 ± 0.20</td>
<td>&lt;.05/.91</td>
</tr>
<tr>
<td><strong>Arteria pulmonalis dexta</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inner/outer diameter (cm)</td>
<td>0.69 ± 0.16/0.93 ± 0.16</td>
<td>0.69 ± 0.20/0.96 ± 0.22</td>
<td>1.00/.81</td>
</tr>
<tr>
<td><strong>Vena cava caudalis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inner/outer diameter (cm)</td>
<td>1.02 ± 0.25/1.23 ± 0.27</td>
<td>1.14 ± 0.31/1.34 ± 0.31</td>
<td>.37/.43</td>
</tr>
<tr>
<td><strong>V. cava cranialis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inner/outer diameter (cm)</td>
<td>1.18 ± 0.29/1.40 ± 0.30</td>
<td>1.06 ± 0.27/1.28 ± 0.29</td>
<td>.38/.39</td>
</tr>
</tbody>
</table>

Bold indicates P < .05. cPAB, Central pulmonary artery banding. *Before right pulmonary artery. |Aorta was cut 4 cm from origin.